# Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.

> **NCT03957733** · PHASE2,PHASE3 · UNKNOWN · sponsor: **King Abdullah Medical City** · enrollment: 338 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03957733
- **Lead sponsor:** King Abdullah Medical City
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-23
- **Primary completion:** 2022-05-30
- **Final completion:** 2025-11-23
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957733, "Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03957733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*